Free Trial

Galectin Therapeutics (GALT) News Today

Galectin Therapeutics logo
$1.39 +0.05 (+3.73%)
As of 10:25 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Galectin Therapeutics Inc. stock logo
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Commonwealth Equity Services LLC
Commonwealth Equity Services LLC lessened its holdings in shares of Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 72.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 134,518 shares of the company's stock after selling 348
Galectin Therapeutics Inc. stock logo
HC Wainwright Analysts Raise Earnings Estimates for GALT
Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Equities researchers at HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for shares of Galectin Therapeutics in a research note issued on Wednesday, April 2nd. HC Wainwright analyst E. Arce now forecasts that the compan
Galectin Therapeutics Inc. stock logo
FY2029 Earnings Forecast for GALT Issued By HC Wainwright
Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Stock analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Galectin Therapeutics in a research note issued to investors on Wednesday, April 2nd. HC Wainwright analyst E. Arce forecasts that the company will post earning
Galectin Therapeutics Inc. stock logo
HC Wainwright Reiterates Neutral Rating for Galectin Therapeutics (NASDAQ:GALT)
HC Wainwright reiterated a "neutral" rating on shares of Galectin Therapeutics in a research note on Wednesday.
Galectin Therapeutics reports FY24 EPS (76c) vs (74c) last year
Galectin Therapeutics Inc. stock logo
Galectin Therapeutics (NASDAQ:GALT) Posts Earnings Results, Misses Estimates By $0.03 EPS
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) issued its earnings results on Monday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03).
Galectin Therapeutics Inc. stock logo
Galectin Therapeutics (GALT) to Release Quarterly Earnings on Friday
Galectin Therapeutics (NASDAQ:GALT) will be releasing earnings before the market opens on Friday, April 4, Financial Modeling Prep reports.
Galectin Therapeutics’ belapectin shows reduction in new varices
Galectin Therapeutics Inc. stock logo
Investors Purchase High Volume of Galectin Therapeutics Put Options (NASDAQ:GALT)
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the recipient of unusually large options trading on Wednesday. Investors acquired 15,740 put options on the stock. This is an increase of 230% compared to the typical volume of 4,772 put options.
Galectin Therapeutics Inc. stock logo
Galectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com to "Sell"
StockNews.com lowered Galectin Therapeutics from a "hold" rating to a "sell" rating in a report on Monday.
Galectin Therapeutics Inc. stock logo
Short Interest in Galectin Therapeutics Inc. (NASDAQ:GALT) Increases By 41.1%
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 8,270,000 shares, a growth of 41.1% from the November 30th total of 5,860,000 shares. Currently, 19.0% of the company's shares are sold short. Based on an average daily volume of 494,900 shares, the short-interest ratio is currently 16.7 days.
Galectin Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Galectin Therapeutics Inc. stock logo
Galectin Therapeutics (NASDAQ:GALT) Earns Neutral Rating from HC Wainwright
HC Wainwright reiterated a "neutral" rating on shares of Galectin Therapeutics in a research note on Friday.
Galectin Therapeutics Inc. stock logo
Khurram Jamil Sells 13,654 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) Stock
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) insider Khurram Jamil sold 13,654 shares of Galectin Therapeutics stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $0.88, for a total transaction of $12,015.52. Following the completion of the transaction, the insider now directly owns 26,346 shares of the company's stock, valued at approximately $23,184.48. This represents a 34.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Galectin Therapeutics Inc. stock logo
Insider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) CFO Sells 40,000 Shares of Stock
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) CFO Jack W. Callicutt sold 40,000 shares of the business's stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.89, for a total transaction of $35,600.00. Following the completion of the transaction, the chief financial officer now directly owns 7,614 shares of the company's stock, valued at $6,776.46. The trade was a 84.01 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Galectin Therapeutics Inc. stock logo
Galectin Therapeutics Inc. (NASDAQ:GALT) CEO Sells 56,000 Shares of Stock
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) CEO Joel Lewis sold 56,000 shares of the stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.89, for a total value of $49,840.00. Following the completion of the sale, the chief executive officer now owns 897,012 shares of the company's stock, valued at $798,340.68. The trade was a 5.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Why Is Galectin Stock Falling In Pre-market?
Galectin drops as trial for lead asset fails in MASH
Galectin Therapeutics Inc. stock logo
Stock Traders Purchase Large Volume of Galectin Therapeutics Put Options (NASDAQ:GALT)
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the target of unusually large options trading activity on Monday. Stock investors bought 14,331 put options on the stock. This represents an increase of 557% compared to the average daily volume of 2,182 put options.
Galectin Therapeutics Inc. stock logo
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by StockNews.com
StockNews.com upgraded Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday.
Galectin Therapeutics Inc. stock logo
HC Wainwright Has Bearish Estimate for GALT FY2027 Earnings
Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Stock analysts at HC Wainwright dropped their FY2027 earnings estimates for shares of Galectin Therapeutics in a research note issued on Friday, November 15th. HC Wainwright analyst E. Arce now expects that the company will post earnings of
Galectin Therapeutics Reports Increased Q3 Losses
Galectin Therapeutics Inc. stock logo
Galectin Therapeutics (NASDAQ:GALT) Given "Buy" Rating at HC Wainwright
HC Wainwright restated a "buy" rating and issued a $11.00 price target on shares of Galectin Therapeutics in a research report on Friday.
Galectin Therapeutics Inc. stock logo
Galectin Therapeutics Inc. (NASDAQ:GALT) Director Purchases $13,500.00 in Stock
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) Director Kevin D. Freeman bought 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 16th. The shares were acquired at an average price of $2.70 per share, with a total value of $13,500.00. Following the completion of the transaction, the director now directly owns 33,469 shares of the company's stock, valued at $90,366.30. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Galectin Therapeutics Inc. stock logo
Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at StockNews.com
StockNews.com upgraded shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday.
Galectin Therapeutics Inc. stock logo
Galectin Therapeutics (NASDAQ:GALT) Rating Increased to Hold at StockNews.com
StockNews.com raised shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday.
Galectin Therapeutics Inc. stock logo
Galectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com
StockNews.com downgraded Galectin Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday.
Galectin Therapeutics Inc. stock logo
Galectin Therapeutics (NASDAQ:GALT) Upgraded at StockNews.com
StockNews.com raised Galectin Therapeutics from a "sell" rating to a "hold" rating in a report on Friday.
Galectin Therapeutics Inc. stock logo
Commonwealth Equity Services LLC Buys 367,610 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT)
Commonwealth Equity Services LLC increased its stake in Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 317.6% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 483,351 shares of the company's stock after buying an ad
Galectin Therapeutics Inc. stock logo
Galectin Therapeutics Inc. (NASDAQ:GALT) Sees Significant Growth in Short Interest
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 5,010,000 shares, a growth of 6.4% from the July 31st total of 4,710,000 shares. Currently, 11.6% of the shares of the company are sold short. Based on an average daily trading volume, of 165,400 shares, the days-to-cover ratio is currently 30.3 days.
Galectin Therapeutics Inc. stock logo
Stock Traders Purchase Large Volume of Put Options on Galectin Therapeutics (NASDAQ:GALT)
Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Traders purchased 2,501 put options on the company. This is an increase of approximately 1,282% compared to the average daily volume of 181 put options.
Get Galectin Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.

GALT Media Mentions By Week

GALT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GALT
News Sentiment

0.00

0.72

Average
Medical
News Sentiment

GALT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GALT Articles
This Week

0

1

GALT Articles
Average Week

Get Galectin Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:GALT) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners